Karyopharm reports second quarter 2024 financial results and highlights recent company progress

– achieves second quarter 2024 total revenue of $42.8 million and u.s. xpovio® (selinexor) net product revenue of $28.0 million; positive momentum ex-us with continued regulatory and reimbursement approvals – – updated clinical results at asco annual meeting showed median progression-free survival (pfs) of 28.4 months in the tp53 wild-type exploratory subgroup and 39.5 months in the proficient mismatched repair status (pmmr) tp53 wild-type exploratory subgroup from phase 3 siendo study of selinexor maintenance treatment in advanced/recurrent endometrial cancer – – pre-clinical data presented at the june 2024 european hematology association meeting support selinexor's mechanism of action targeting multiple oncogenic pathways beyond jak/stat and builds on the compelling clinical data in myelofibrosis – – completed significant refinancing transactions and amended royalty agreement with healthcare royalty extending vast majority of its debt maturities into 2028 and 2029, well beyond expected data readouts and potential approvals from the company's three phase 3 trials, strengthening the company for its next stage of growth – –  raises the lower end of full-year 2024 total revenue guidance to $145.0 million to $160.0 million and u.s. xpovio net product revenue guidance to $105.0 million to $120.0 million; lowers full year 2024 r&d and sg&a expense guidance to $250.0 million to $265.0 million – newton, mass. , aug. 6, 2024 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended june 30, 2024, and highlighted select corporate milestones and progress on its key clinical development programs.
KPTI Ratings Summary
KPTI Quant Ranking